Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 May;70(5):574–579. doi: 10.1136/jnnp.70.5.574

Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

J Bryant 1, A Clegg 1, R Milne 1
PMCID: PMC1737368  PMID: 11309449

Abstract

OBJECTIVE—To review the clinical effectiveness and costs of a range of disease modifying drugs in multiple sclerosis. Drugs included are azathioprine, cladribine, cyclophosphamide, intravenous immunoglobulin, methotrexate, and mitoxantrone.
METHODS—Electronic databases and bibliographies of related papers were searched for randomised controlled trials (RCTs) and systematic reviews, and experts and pharmaceutical companies were contacted for further information. Inclusion and quality criteria were assessed, data extraction undertaken by one reviewer and checked by a second reviewer, with discrepancies being resolved through discussion. Costs were obtained and cost-effectiveness papers sought.
RESULTS—Seventeen studies met the inclusion criteria for the review. Evidence for the clinical effectiveness of the drugs showed some reductions in relapse rates and/or progression to disability for people with MS, although benefits may be lessened by wide ranging side effects. Annual drug costs/patient are estimated to range from £60 to £10 200. No cost effectiveness studies were found.
CONCLUSION—Evidence for the effectiveness of these drugs in multiple sclerosis is problematic because there are few good quality trials for each drug. Trials often have methodological limitations and use different treatment regimes, patient groups, and outcome measures. Well conducted trials using outcome measures with clinical significance for groups of patients with different types of multiple sclerosis and long term follow up are needed if the evidence base of treatment for the disease is to be improved.



Full Text

The Full Text of this article is available as a PDF (130.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Achiron A., Gabbay U., Gilad R., Hassin-Baer S., Barak Y., Gornish M., Elizur A., Goldhammer Y., Sarova-Pinhas I. Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology. 1998 Feb;50(2):398–402. doi: 10.1212/wnl.50.2.398. [DOI] [PubMed] [Google Scholar]
  2. Beutler E., Sipe J. C., Romine J. S., Koziol J. A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716–1720. doi: 10.1073/pnas.93.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bryant J., Clegg A., Milne R. Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast. BMJ. 2000 May 27;320(7247):1474–1476. [PMC free article] [PubMed] [Google Scholar]
  4. Currier R. D., Haerer A. F., Meydrech E. F. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 1993 Nov;56(11):1217–1218. doi: 10.1136/jnnp.56.11.1217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Edan G., Miller D., Clanet M., Confavreux C., Lyon-Caen O., Lubetzki C., Brochet B., Berry I., Rolland Y., Froment J. C. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997 Feb;62(2):112–118. doi: 10.1136/jnnp.62.2.112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997 Mar 1;349(9052):589–593. doi: 10.1016/s0140-6736(96)09377-4. [DOI] [PubMed] [Google Scholar]
  7. Goodkin D. E., Rudick R. A., VanderBrug Medendorp S., Daughtry M. M., Schwetz K. M., Fischer J., Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 Jan;37(1):30–40. doi: 10.1002/ana.410370108. [DOI] [PubMed] [Google Scholar]
  8. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  9. Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
  10. Jüni P., Witschi A., Bloch R., Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999 Sep 15;282(11):1054–1060. doi: 10.1001/jama.282.11.1054. [DOI] [PubMed] [Google Scholar]
  11. Kappos L., Moeri D., Radue E. W., Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann C. R., Weiner H. L., Gasperini C. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999 Mar 20;353(9157):964–969. doi: 10.1016/s0140-6736(98)03053-0. [DOI] [PubMed] [Google Scholar]
  12. Killian J. M., Bressler R. B., Armstrong R. M., Huston D. P. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol. 1988 Jan;45(1):27–30. doi: 10.1001/archneur.1988.00520250033014. [DOI] [PubMed] [Google Scholar]
  13. Likosky W. H., Fireman B., Elmore R., Eno G., Gale K., Goode G. B., Ikeda K., Laster J., Mosher C., Rozance J. Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry. 1991 Dec;54(12):1055–1060. doi: 10.1136/jnnp.54.12.1055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Milanese C., La Mantia L., Salmaggi A., Eoli M. A double blind study on azathioprine efficacy in multiple sclerosis: final report. J Neurol. 1993 May;240(5):295–298. doi: 10.1007/BF00838165. [DOI] [PubMed] [Google Scholar]
  15. Millefiorini E., Gasperini C., Pozzilli C., D'Andrea F., Bastianello S., Trojano M., Morino S., Morra V. B., Bozzao A., Calo' A. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol. 1997 Mar;244(3):153–159. doi: 10.1007/s004150050066. [DOI] [PubMed] [Google Scholar]
  16. Romine J. S., Sipe J. C., Koziol J. A., Zyroff J., Beutler E. A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):35–44. doi: 10.1046/j.1525-1381.1999.09115.x. [DOI] [PubMed] [Google Scholar]
  17. Sorensen P. S., Wanscher B., Jensen C. V., Schreiber K., Blinkenberg M., Ravnborg M., Kirsmeier H., Larsen V. A., Lee M. L. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology. 1998 May;50(5):1273–1281. doi: 10.1212/wnl.50.5.1273. [DOI] [PubMed] [Google Scholar]
  18. Steck A. J., Regli F., Ochsner F., Gauthier G. Cyclosporine versus azathioprine in the treatment of multiple sclerosis: 12-month clinical and immunological evaluation. Eur Neurol. 1990;30(4):224–228. doi: 10.1159/000117351. [DOI] [PubMed] [Google Scholar]
  19. Weiner H. L., Mackin G. A., Orav E. J., Hafler D. A., Dawson D. M., LaPierre Y., Herndon R., Lehrich J. R., Hauser S. L., Turel A. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May;43(5):910–918. doi: 10.1212/wnl.43.5.910. [DOI] [PubMed] [Google Scholar]
  20. Yudkin P. L., Ellison G. W., Ghezzi A., Goodkin D. E., Hughes R. A., McPherson K., Mertin J., Milanese C. Overview of azathioprine treatment in multiple sclerosis. Lancet. 1991 Oct 26;338(8774):1051–1055. doi: 10.1016/0140-6736(91)91909-e. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES